Surface Oncology Presents Promising Preclinical Data for Lead Immunotherapy Product Candidates at the American Association for Cancer Research Annual Meeting

Surface Oncology’s SRF617 Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer

Surface Oncology to Present Preclinical Data for Lead Product Programs at the American Association for Cancer Research Annual Meeting

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020

Surface Oncology to Collaborate with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

Surface Oncology to Participate in Upcoming March Investor Conferences

Surface Oncology to Appoint Robert Ross, M.D., as President and Chief Executive Officer

Surface Oncology to Participate in H.C. Wainwright Bioconnect 2021 Conference